DeepMed Research

Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Clinical Trials

Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A Randomized Controlled Trial

Phase 3

Completed

Conditions: Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones

Interventions: Drug: Tamsulosin Oral Capsule
Drug: Placebo

First Posted Date: 2020-09-21

Last Posted Date: 2020-09-21

Lead Sponsor: Ain Shams University

Target Recruit Count: 120

Registration Number: NCT04557202

Locations: 🇪🇬
Urology department - ain shams university, Cairo, Egypt

Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

Phase 2

Completed

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Interventions: Drug: Ciprofloxacin
Drug: Tamsulosin Hydrochloride
Drug: Ciprofloxacin placebo
Drug: Tamsulosin Hydrochloride Placebo

First Posted Date: 2020-09-17

Last Posted Date: 2020-09-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 196

Registration Number: NCT04552431

Study to Prevent Postoperative Urinary Retention

Phase 4

Recruiting

Conditions: Inguinal Hernia
Urinary Retention

Interventions: Drug: Control Intervention
Drug: TAMSULOSIN Mepha Ret Depocaps 0.4 mg

First Posted Date: 2020-07-29

Last Posted Date: 2023-03-10

Lead Sponsor: Antonio Nocito, MD

Target Recruit Count: 634

Registration Number: NCT04491526

Locations: 🇨🇭
Kantonsspital Baden, Baden, Aargau, Switzerland

Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair

Phase 4

Terminated

Conditions: Post Operative Urinary Retention

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: Jewish Hospital, Cincinnati, Ohio

Target Recruit Count: 170

Registration Number: NCT04434378

Locations: 🇺🇸
Jewish Hospital, Cincinnati, Ohio, United States

Tamsulosin for Thyroid Lid Retraction

Not Applicable

Conditions: Thyroid Eye Disease
Eyelid Diseases

Interventions: Drug: Tamsulosin

First Posted Date: 2020-04-24

Last Posted Date: 2022-06-23

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 50

Registration Number: NCT04359979

Locations: 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Phase 3

Conditions: Ureteral Stent
Stent Related Symptoms

Interventions: Drug: Placebo oral tablet
Drug: Mirabegron 50 MG
Drug: Tamsulosin
Drug: Solifenacin Succinate 10 MG

First Posted Date: 2020-03-30

Last Posted Date: 2021-11-23

Lead Sponsor: Mansoura University

Target Recruit Count: 240

Registration Number: NCT04325880

Locations: 🇪🇬
Urology and Nephrology Center, Mansoura, DK, Egypt

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

Early Phase 1

Active, not recruiting

Conditions: Urinary Retention

Interventions: Drug: Tamsulosin 0.4Mg Capsule
Drug: Placebo oral tablet

First Posted Date: 2020-01-18

Last Posted Date: 2025-05-21

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 100

Registration Number: NCT04232683

Locations: 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States

REduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial

Phase 3

Conditions: Urinary Catheterization
Thoracic Surgery
Thoracic Epidural Analgesia

Interventions: Drug: Placebos
Drug: Tamsulosin Hydrochloride

First Posted Date: 2019-11-12

Last Posted Date: 2021-02-25

Lead Sponsor: McMaster University

Target Recruit Count: 350

Registration Number: NCT04159077

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: IGRT 45 Gy in 5 fractions of 9 Gy
Radiation: IGRT 24 Gy single dose
Drug: Dexamethasone
Drug: Tamsulosin

First Posted Date: 2019-11-01

Last Posted Date: 2024-06-11

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 30

Registration Number: NCT04147806

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Silodosin
Drug: Tamsulosin

First Posted Date: 2019-09-27

Last Posted Date: 2019-09-27

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 141

Registration Number: NCT04107896

Locations: 🇧🇩
Maidul islam, Dhaka, Bangladesh

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy